問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Psychiatry

Division of Ophthalmology

Division of General Internal Medicine

更新時間:2023-09-19

黃介良
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

15Cases

2005-01-01 - 2008-11-01

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2022-07-01 - 2024-09-20

Phase III

Completed
A 6-Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Cariprazine in the Acute Exacerbation of Schizophrenia, with an Additional 18-Week Blinded Extension Period
  • Condition/Disease

    Schizophrenia

  • Test Drug

    Cariprazine

Participate Sites
16Sites

Not yet recruiting3Sites

Recruiting11Sites

Terminated2Sites

2020-12-01 - 2025-08-31

Phase II/III

Completed
A Phase 2B Randomized, Double-Blind, Placebo-and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia
  • Condition/Disease

    Schizophrenia

  • Test Drug

    MK-8189

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting4Sites

-

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

2008-01-31 - 2009-02-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-03-01 - 2009-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-04-17 - 2018-11-09

Phase III

A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder
  • Condition/Disease

    Insomnia Disorder

  • Test Drug

    Lemborexant (E2006)

Participate Sites
2Sites

Terminated2Sites

2015-12-01 - 2017-12-31

Phase III

An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients with Opioid Use Disorder.
  • Condition/Disease

    opioid use disorder

  • Test Drug

    CAM2038 q1w(buprenorphine FluidCrystal®每週一次長效注射劑); CAM2038 q4w(buprenorphine FluidCrystal®每月一次長效注射劑)

Participate Sites
3Sites

Terminated3Sites

1 2